FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

PNC-27

p53-MDM2 Peptide

Fat Loss & Body Composition

PNC-27 is a synthetic anti-cancer peptide consisting of a sequence derived from the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating (HDM-2 binding) domain that selectively targets and destroys cancer cells expressing HDM-2 (Human Double Minute 2) on their surface membrane. Unlike most chemotherapeutic agents, PNC-27 induces rapid membranolysis (membrane destruction) and necrosis specifically in cancer cells while leaving normal cells unaffected due to the absence of surface HDM-2 in healthy tissue. It remains in the preclinical research stage with no human clinical trials completed.

Wirkmechanismus

Chimeric peptide combining an HDM-2 binding domain with a cell-penetrating sequence. Selectively targets cells with membrane-associated HDM-2 (overexpressed in many cancer cells), creating pores that trigger necrosis. Spares normal cells lacking surface HDM-2.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Research is primarily in vitro and animal models. No established human dosing protocols. Cancer research studies used 50-200mcg/ml in cell culture. In vivo studies used local injection into tumors.

Forschungsnotizen

Clinical Research Status

PNC-27 has been extensively studied in preclinical cell culture and animal models by the research group of Dr. Ehsan Ehsanipour and collaborators, with publications spanning multiple cancer cell types over the past two decades. No human clinical trials have been registered or completed, and the compound remains firmly in the laboratory research phase. The selective cytotoxicity demonstrated in vitro has generated significant interest, but translation to clinical use faces challenges including peptide stability, delivery, pharmacokinetics, and manufacturing at therapeutic scale.

Key Published Findings

Studies demonstrate that PNC-27 induces rapid necrosis (within hours) in multiple cancer cell lines including breast (MDA-MB-231, MCF-7), pancreatic (MIA PaCa-2), and leukemia cells while showing no toxicity to normal cells at equivalent concentrations. The mechanism involves binding to HDM-2 protein aberrantly expressed on the surface of cancer cells (but not normal cells), leading to membrane pore formation, loss of membrane integrity, and necrotic cell death. Importantly, the cytotoxic mechanism is independent of p53 status in the cancer cell, meaning it can kill p53-mutant cancers that are resistant to conventional therapies.

Safety Profile

In vitro studies consistently show that PNC-27 has no cytotoxic effect on normal human fibroblasts, lymphocytes, or other non-transformed cells at concentrations that kill cancer cells. Animal studies using xenograft tumor models have not reported significant systemic toxicity at effective anti-tumor doses. However, comprehensive toxicology studies, pharmacokinetic profiling, and maximum tolerated dose determinations have not been published, and the peptide's behavior in complex human physiology remains unknown.

Comparison to Related Compounds

PNC-27 is unique among anti-cancer peptides in targeting a specific oncogenic surface marker (HDM-2) rather than general differences in membrane charge or composition that other antimicrobial/anticancer peptides exploit. Unlike conventional chemotherapy which kills rapidly dividing cells indiscriminately, PNC-27's selectivity is based on a molecular marker of malignant transformation. Compared to antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, PNC-27 represents a simpler molecular approach but faces similar challenges in tumor penetration and peptide drug delivery.

Community Observations

PNC-27 generates significant interest in alternative cancer research communities due to its selectivity and novel mechanism, though access outside of research settings is essentially impossible. The peptide is occasionally discussed in online forums alongside other experimental cancer compounds, with patients and advocates expressing frustration at the slow pace of clinical translation. Legitimate researchers caution that impressive in vitro results do not guarantee clinical efficacy, as many promising cancer compounds fail in the transition from cell culture to human patients.

Halbwertszeit

~Unknown

Rekonstitution

Sterile PBS or bacteriostatic water

Lagerung

Lyophilisiert

Store at -20C. Extremely sensitive to degradation.

Rekonstituierter

Prepare fresh. Use within 24 hours.

Rechtsstatus USA

Research chemical (not FDA-approved)

Auch bekannt als

p53-MDM2 Peptide

Häufig gestellte Fragen

Was ist PNC-27?

PNC-27 is a synthetic anti-cancer peptide consisting of a sequence derived from the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating (HDM-2 binding) domain that selectively targets and destroys cancer cells expressing HDM-2 (Human Double Minute 2) on their surface membrane. Unlike most chemotherapeutic agents, PNC-27 induces rapid membranolysis (membrane destruction) and necrosis specifically in cancer cells while leaving normal cells unaffected due to the absence of surface HDM-2 in healthy tissue. It remains in the preclinical research stage with no human clinical trials completed.

Wie wirkt PNC-27?

Chimeric peptide combining an HDM-2 binding domain with a cell-penetrating sequence. Selectively targets cells with membrane-associated HDM-2 (overexpressed in many cancer cells), creating pores that trigger necrosis. Spares normal cells lacking surface HDM-2.

Wie ist der regulatorische Status von PNC-27 in den USA?

Research chemical (not FDA-approved)

Wie lang ist die Halbwertszeit von PNC-27?

~Unknown

Wie wird PNC-27 noch genannt?

p53-MDM2 Peptide

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen